These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11354352)

  • 1. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.
    Jabs DA; Rosenbaum JT
    Am J Ophthalmol; 2001 May; 131(5):679. PubMed ID: 11354352
    [No Abstract]   [Full Text] [Related]  

  • 2. HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha.
    Kötter I; Aepinus C; Graepler F; Gärtner V; Eckstein AK; Stübiger N; Kaskas B; Zierhut M; Bültmann B; Kandolf R; Kanz L
    Ann Rheum Dis; 2001 Jan; 60(1):83-6. PubMed ID: 11114291
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of interferon-alpha in Behçet's disease--review of the literature and possible mechanisms of action.
    Kötter I; Günaydin I; Treusch M; Zierhut M; Kanz L; Stübiger N
    Adv Exp Med Biol; 2003; 528():503-9. PubMed ID: 12918753
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-alpha 2a treatment of neuro-Behcet disease.
    Nichols JC; Ince A; Akduman L; Mann ES
    J Neuroophthalmol; 2001 Jun; 21(2):109-11. PubMed ID: 11450899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of interferon-alpha 2b in Behçet's disease.
    Durand JM; Kaplanski G; Telle H; Soubeyrand J; Paulo F
    Arthritis Rheum; 1993 Jul; 36(7):1025-6. PubMed ID: 8318030
    [No Abstract]   [Full Text] [Related]  

  • 6. Behçet's syndrome.
    Stanford MR
    Br J Ophthalmol; 2003 Apr; 87(4):381-2. PubMed ID: 12642292
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of ocular manifestations of Behçet's disease.
    Davatchi F
    Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96).
    Onal S; Tugal-Tutkun I
    Ophthalmology; 2014 Oct; 121(10):e57-8. PubMed ID: 25064722
    [No Abstract]   [Full Text] [Related]  

  • 10. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients.
    Lee JH; Lee CS; Lee SC
    BMC Ophthalmol; 2018 Feb; 18(1):52. PubMed ID: 29463220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease.
    Stuebiger N; Koetter I; Zierhut M
    Br J Ophthalmol; 2000 Dec; 84(12):1437-8. PubMed ID: 11186866
    [No Abstract]   [Full Text] [Related]  

  • 13. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
    Evereklioglu C; Borlu M
    Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
    Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
    Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
    Kötter I; Zierhut M; Eckstein A; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Kanz L; Stübiger N
    Adv Exp Med Biol; 2003; 528():521-3. PubMed ID: 12918755
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuro-Behçet syndrome presenting as acute meningeal syndrome.
    Kara B; Somer A; Pişkin S; Aydinli N; Salman N; Yalçin I
    J Infect; 2006 Apr; 52(4):e120-3. PubMed ID: 16197999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha 2b for refractory ocular Behçet's disease.
    Durand JM; Soubeyrand J
    Lancet; 1994 Jul; 344(8918):333. PubMed ID: 7914275
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon-alpha 2b for refractory ocular Behçet's disease.
    Feron EJ; Rothova A; van Hagen PM; Baarsma GS; Suttorp-Schulten MS
    Lancet; 1994 Jun; 343(8910):1428. PubMed ID: 7910903
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis.
    Hasanreisoglu M; Cubuk MO; Ozdek S; Gurelik G; Aktas Z; Hasanreisoglu B
    Ocul Immunol Inflamm; 2017 Feb; 25(1):71-75. PubMed ID: 26910383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy in Behçet's disease.
    Okada AA
    Ocul Immunol Inflamm; 2000 Jun; 8(2):85-91. PubMed ID: 10980680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.